Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis

NCT04607837 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04607837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 12, 2021
Completion date
June 19, 2024
Enrollment
234 (actual)
Sites
288

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis